Dataset Information


Sotrastaurin, a protein kinase C inhibitor, ameliorates ischemia and reperfusion injury in rat orthotopic liver transplantation.

ABSTRACT: Sotraustaurin (STN), a small molecule, targeted protein kinase C (PKC) inhibitor that prevents T-lymphocyte activation via a calcineurin-independent pathway, is currently being tested in Phase II renal and liver transplantation clinical trials. We have documented the key role of activated T cells in the inflammation cascade leading to liver ischemia/reperfusion injury (IRI). This study explores putative cytoprotective functions of STN in a clinically relevant rat model of hepatic cold ischemia followed by orthotopic liver transplantation (OLT). Livers from Sprague-Dawley rats were stored for 30 h at 4°C in UW solution, and then transplanted to syngeneic recipients. STN treatment of liver donors/recipients or recipients only prolonged OLT survival to >90% (vs. 40% in controls), decreased hepatocellular damage and improved histological features of IRI. STN treatment decreased activation of T cells, and diminished macrophage/neutrophil accumulation in OLTs. These beneficial effects were accompanied by diminished apoptosis, NF-?B/ERK signaling, depressed proapoptotic cleaved caspase-3, yet upregulated antiapoptotic Bcl-2/Bcl-xl and hepatic cell proliferation. In vitro, STN decreased PKC?/I?B? activation and IL-2/IFN-? production in ConA-stimulated spleen T cells, and diminished TNF-?/IL-1? in macrophage-T cell cocultures. This study documents positive effects of STN on liver IRI in OLT rat model that may translate as an additional benefit of STN in clinical liver transplantation.

PROVIDER: S-EPMC3625141 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC3535503 | BioStudies
| S-EPMC6033647 | BioStudies
| S-EPMC6773499 | BioStudies
| S-EPMC6620163 | BioStudies
2016-12-08 | GSE87487 | GEO
| S-EPMC5444987 | BioStudies
| S-EPMC6035063 | BioStudies
2019-01-01 | S-EPMC6668671 | BioStudies
| S-EPMC4729306 | BioStudies
| S-EPMC7190917 | BioStudies